Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques
- PMID: 15105094
- PMCID: PMC400569
- DOI: 10.1128/AAC.48.5.1469-1487.2004
Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques
Erratum in
- Antimicrob Agents Chemother. 2994 Jan;48(6):2346
Abstract
The reverse transcriptase inhibitor 9-[2-(phosphonomethoxy)propyl]adenine (PMPA; tenofovir) was previously found to offer strong prophylactic and therapeutic benefits in an infant macaque model of pediatric human immunodeficiency virus (HIV) infection. We now summarize the toxicity and safety of PMPA in these studies. When a range of PMPA doses (4 to 30 mg/kg of body weight administered subcutaneously once daily) was administered to 39 infant macaques for a short period of time (range, 1 day to 12 weeks), no adverse effects on their health or growth were observed; this included a subset of 12 animals which were monitored for more than 2 years. In contrast, daily administration of a high dose of PMPA (30 mg/kg subcutaneously) for prolonged periods of time (>8 to 21 months) to 13 animals resulted in a Fanconi-like syndrome (proximal renal tubular disorder) with glucosuria, aminoaciduria, hypophosphatemia, growth restriction, bone pathology (osteomalacia), and reduced clearance of PMPA. The adverse effects were reversible or were alleviated following either complete withdrawal of PMPA treatment or reduction of the daily regimen from 30 mg/kg to 2.5 to 10 mg/kg subcutaneously. Finally, to evaluate the safety of a prolonged low-dose treatment regimen, two newborn macaques were started on a 10-mg/kg/day subcutaneous regimen; these animals are healthy and have normal bone density and growth after 5 years of daily treatment. In conclusion, our findings suggest that chronic daily administration of a high dose of PMPA results in adverse effects on kidney and bone, while short-term administration of relatively high doses and prolonged low-dose administration are safe.
Figures
Similar articles
-
Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies.J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 1;20(4):323-33. doi: 10.1097/00042560-199904010-00001. J Acquir Immune Defic Syndr Hum Retrovirol. 1999. PMID: 10096575
-
Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection.AIDS. 1998 Jun 18;12(9):F79-83. doi: 10.1097/00002030-199809000-00001. AIDS. 1998. PMID: 9662190
-
Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.J Virol. 2000 Feb;74(4):1767-74. doi: 10.1128/jvi.74.4.1767-1774.2000. J Virol. 2000. PMID: 10644348 Free PMC article.
-
Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.Clin Ther. 2002 Oct;24(10):1515-48. doi: 10.1016/s0149-2918(02)80058-3. Clin Ther. 2002. PMID: 12462284 Review.
-
Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.Antiviral Res. 2016 Jan;125:63-70. doi: 10.1016/j.antiviral.2015.11.009. Epub 2015 Nov 27. Antiviral Res. 2016. PMID: 26640223 Review.
Cited by
-
Polymer-Based Nanoparticles as Drug Delivery Systems for Purines of Established Importance in Medicine.Nanomaterials (Basel). 2023 Sep 26;13(19):2647. doi: 10.3390/nano13192647. Nanomaterials (Basel). 2023. PMID: 37836288 Free PMC article. Review.
-
Subtrochanteric Pathological Femur Fracture in an HIV-Positive Patient on Tenofovir-based antiretroviral therapy: A Case Report and Review of the Literature.J Orthop Case Rep. 2023 Feb;13(2):14-20. doi: 10.13107/jocr.2023.v13.i02.3538. J Orthop Case Rep. 2023. PMID: 37144071 Free PMC article.
-
Integration of High-Throughput Imaging and Multiparametric Metabolic Profiling Reveals a Mitochondrial Mechanism of Tenofovir Toxicity.Function (Oxf). 2022 Dec 24;4(1):zqac065. doi: 10.1093/function/zqac065. eCollection 2023. Function (Oxf). 2022. PMID: 36654930 Free PMC article.
-
Effects of Long-Term Tenofovir and Entecavir Treatment on Bone Mineral Density in Patients with Chronic Hepatitis B.Turk J Gastroenterol. 2022 Jan;33(1):35-43. doi: 10.5152/tjg.2020.18024. Turk J Gastroenterol. 2022. PMID: 35040786 Free PMC article.
-
Influence of maternal use of tenofovir disoproxil fumarate or zidovudine in Vietnamese pregnant women with HIV on infant growth, renal function, and bone health.PLoS One. 2021 Apr 29;16(4):e0250828. doi: 10.1371/journal.pone.0250828. eCollection 2021. PLoS One. 2021. PMID: 33914827 Free PMC article.
References
-
- Alpers, C. E., C. C. Tsai, K. L. Hudkins, Y. Cui, L. Kuller, R. E. Benveniste, J. M. Ward, and W. R. Morton. 1997. Focal segmental glomerulosclerosis in primates infected with a simian immunodeficiency virus. AIDS Res. Hum. Retrovir. 13:413-424. - PubMed
-
- Barditch-Crovo, P., S. G. Deeks, A. Collier, S. Safrin, D. F. Coakley, M. Miller, B. P. Kearney, R. L. Coleman, P. D. Lamy, J. O. Kahn, I. McGowan, and P. S. Lietman. 2001. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus type 1-infected adults. Antimicrob. Agents Chemother. 45:2733-2739. - PMC - PubMed
-
- Biesecker, G., S. Karimi, J. Desjardins, D. Meyer, B. Abbott, R. Bendele, and F. Richardson. 2003. Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treatment rats, rhesus monkeys and woodchucks. Antivir. Res. 58:217-225. - PubMed
-
- Bourne, G. H. 1975. Nutrition of the rhesus monkey, p. 97-116. In G. H. Bourne (ed.), The rhesus monkey, vol. II. Management, reproduction, and pathology. Academic Press, Inc., New York, N.Y.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical